Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Homewood, Alabama 35209


Purpose:

The purpose of this trial is to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who are scheduled to undergo subsequent radiotherapy for treatment of their prostate cancer. Prior to receiving radiotherapy, it is recommended that patients with intermediate to high risk prostate cancer are pre-treated with hormone therapy (so-called neoadjuvant therapy) which is known to reduce the size of the prostate and thereby decrease the required radiation field and enable a more safe and effective treatment. In this trial, hormone therapy will be given for three months and patients will be randomly selected (like flipping a coin) to receive either Degarelix given alone or a standard hormone therapy (combination of goserelin and bicalutamide) The prostate size will be measured by ultra sound at the beginning and at the end of the trial and patients will be required to come to the clinic for 5 or 6 visits during the three months.


Criteria:

Inclusion Criteria: - Patient has given written informed consent before any trial-related activity is performed. - Has a confirmed prostate cancer in which this type of treatment is needed. Exclusion Criteria: - Previous treatment for prostate cancer - Previous trans-urethral resection of the prostate - Patients who are lymph node positive or have other metastatic disease - Use of urethral catheter - Current treatment with a 5-alpha reductase inhibitor or α-adrenoceptor antagonist. - History of severe untreated asthma, anaphylactic reactions, or severe urticaria and/or angioedema. - Hypersensitivity towards any component of the investigational product - Other previous cancers within the last five years with the exception of prostate cancer and some types of skin cancer. - Certain risk factors for abnormal heart rhythms/QT prolongation (corrected QT interval over 450 msec., Torsades de Pointes or use of certain medications with potential risk) - Clinical disorders other than prostate cancer including but not limited to renal, haematological, gastrointestinal, endocrine, cardiac, neurological, psychiatric disease, alcohol or drug abuse or other conditionals as judged by the investigator.


NCT ID:

NCT00833248


Primary Contact:

Study Director
Clinical Development Support
Ferring Pharmaceuticals


Backup Contact:

N/A


Location Contact:

Homewood, Alabama 35209
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.